

Like DNA Replication, Eukaryotic DNA Mismatch Repair is Asymmetric

June 19th 2012

Sascha Emilie Liberti
DNA replication fidelity group
NIEHS





Polymerase Mutator Alleles – The Toolset


Strand-Specific Error Signature

| | Motif A | Family B |
|------------------|--|----------|
| S.cer α | 863 M D F N S L Y P S I I Q E F N | 877 |
| S.cer δ | 607 L D F N S L Y P S I M M A H N | 621 |
| S.cer ϵ | 639 V D V A S M Y P N I M T T N R | 653 |


- Pol α L868M
- Pol δ L612M
- Pol ϵ M644G



Kunkel and Burgers 2008





Division of Labor at the Eukaryotic Replication Fork




Pursell et al. (2007)
Nick McElhinny et al. (2008)
Kunkel & Burgers (2008)
Larrea et al. PNAS (2010)

DNA mismatch repair



MMR more efficiently repairs errors introduced by pol α than pol δ


Nick McElhinny et. al. PNAS 2010



Working hypothesis


Is Exo I involved in the higher
MMR efficiency observed for
pol α errors?

Mutation rates in *exo1* Δ strains



* Hombauer et al., 2011 *Cell*


Mutation rates in *exo1* Δ strains



Exo I dependent increase in mutation rate
 $pol\ \alpha > pol\ \delta > pol\ \epsilon$

* Hombauer et al., 2011 | *Cell*

Mutation rates in *exo1* Δ strains



Little involvement of *Exo1* in repair of *pol* ϵ errors


* Hombauer et al., 2011 *Cell*

Mutations in *exo* / Δ strains are base substitutions and single base deletions


Indicative of MMR loss

Mutation Specificity in *pol1-L868M* *exo1* Δ and *pol3-L612M* *exo1* Δ strains

pol1-L868M




pol3-L612M



Wild type and Msh2 data are from:
Nick McElhinny et. al. PNAS 2010

Mutation Specificity in *pol1-L868M* *exo1* Δ and *pol3-L612M* *exo1* Δ strains

pol1-L868M




Wild type
 exo1 Δ
 msh2 Δ

Correction factor:

$$\frac{exo1 \Delta}{EXO1^+}$$


pol3-L612M



Wild type and Msh2 data are from:
Nick McElhinny et. al. PNAS 2010

Mutation Specificity in *pol1-L868M exo1Δ* and *pol3-L612M exo1Δ* strains

pol1-L868M




Wild type
 exo1Δ
 msh2Δ

Correction factor:

$$\frac{exo1\Delta}{EXO1^+}$$


pol3-L612M



Wild type and Msh2 data are from:
Nick McElhinny et. al. PNAS 2010

Mutation Specificity in *pol1-L868M* *exo1* Δ and *pol3-L612M* *exo1* Δ strains


pol1-L868M



Wild type
 exo1 Δ
 msh2 Δ

Exo I repairs replication errors introduced by *pol* α more efficiently compared to errors introduced by *pol* δ


pol3-L612M




Wild type and Msh2 data are from:
Nick McElhinny et. al. PNAS 2010

Exo I dependent mismatch repair of transitions

pol1-L868M



pol3-L612M



■ *Exo I* dependent MMR
■ Msh2 dependent MMR

In the absence of Exo I most replication errors can still be corrected through Msh2-dependent mechanisms

MMR deficient strains (*msh2*Δ) are characterized by very high single base deletion rates at four specific mononucleotide runs in *URA3*

Four mononucleotide runs in *URA3* are highly dependent on MMR

| Specific rate at hotspot at 627 ΔG | | Relative increase |
|------------------------------------|-------|-------------------|
| Pol3LM | 0.012 | 1 |
| Pol3LM msh2Δ | 16 | 1300 |
| Pol3LM exo1 Δ | 0.1 | 8 |

| Specific rate at hotspot at 605 ΔC | | Relative increase |
|------------------------------------|-------|-------------------|
| Pol3LM | 0.012 | 1 |
| Pol3LM msh2Δ | 13 | 1000 |
| Pol3LM exo1 Δ | 0.1 | 8 |

| Specific rate at hotspot at 255 ΔT | | Relative increase |
|------------------------------------|-------|-------------------|
| Pol3LM | 0.012 | 1 |
| Pol3LM msh2Δ | 90 | 7200 |
| Pol3LM exo1 Δ | 0.1 | 8 |

| Specific rate at hotspot at 201 ΔT | | Relative increase |
|------------------------------------|-------|-------------------|
| Pol3LM | 0.012 | 1 |
| Pol3LM msh2Δ | 80 | 6500 |
| Pol3LM exo1 Δ | 0.38 | 31 |

Four mononucleotide runs in *URA3* are highly dependent on MMR

| Specific rate at hotspot at 627 Δ G | | | Relative increase |
|--|-------|--|-------------------|
| Pol3LM | 0.012 | | 1 |
| Pol3LM msh2 Δ | 16 | | 1300 |
| Pol3LM exo1 Δ | 0.1 | | 8 |

| Specific rate at hotspot at 605 Δ C | | | Relative increase |
|--|-------|--|-------------------|
| Pol3LM | 0.012 | | 1 |
| Pol3LM msh2 Δ | 13 | | 1000 |
| Pol3LM exo1 Δ | 0.1 | | 8 |

| Specific rate at hotspot at 255 Δ T | | | Relative increase |
|--|-------|--|-------------------|
| Pol3LM | 0.012 | | 1 |
| Pol3LM msh2 Δ | 90 | | 7200 |
| Pol3LM exo1 Δ | 0.1 | | 8 |

| Specific rate at hotspot at 201 Δ T | | | Relative increase |
|--|-------|--|-------------------|
| Pol3LM | 0.012 | | 1 |
| Pol3LM msh2 Δ | 80 | | 6500 |
| Pol3LM exo1 Δ | 0.38 | | 31 |

Four mononucleotide runs in *URA3* are highly dependent on MMR –
But not on Exo I



| Specific rate at hotspot at 627 Δ G | | |
|--|---------------|-------------------|
| | Specific rate | Relative increase |
| Pol3LM | 0.012 | 1 |
| Pol3LM msh2 Δ | 16 | 1300 |
| Pol3LM exo I Δ | 0.1 | 8 |

| Specific rate at hotspot at 605 Δ C | | |
|--|---------------|-------------------|
| | Specific rate | Relative increase |
| Pol3LM | 0.012 | 1 |
| Pol3LM msh2 Δ | 13 | 1000 |
| Pol3LM exo I Δ | 0.1 | 8 |

| Specific rate at hotspot at 255 Δ T | | |
|--|---------------|-------------------|
| | Specific rate | Relative increase |
| Pol3LM | 0.012 | 1 |
| Pol3LM msh2 Δ | 90 | 7200 |
| Pol3LM exo I Δ | 0.1 | 8 |



| Specific rate at hotspot at 201 Δ T | | |
|--|---------------|-------------------|
| | Specific rate | Relative increase |
| Pol3LM | 0.012 | 1 |
| Pol3LM msh2 Δ | 80 | 6500 |
| Pol3LM exo I Δ | 0.38 | 31 |

Dissection of Exo I's functions in MMR sub-pathways



Hypothesis:
Exo I is not significantly involved in repair of replication errors through the Msh2-Msh3 sub-pathway of MMR

Dissection of Exo I's functions in MMR sub-pathways



Mutation Specificity in *exo1* Δ and *msh3* Δ strains

MMR of -T in a run of Ts in *pol3-L612M*

| Strain | Rate ($\times 10^{-7}$) |
|---|---------------------------|
| MSH2 | 0.006 |
| <i>msh2</i> Δ | 37 |
| <i>msh6</i> Δ | 0.54 |
| <i>msh3</i> Δ | 0.05 |
| <i>msh3</i> Δ <i>msh6</i> Δ | 19 (synergy) |

Mutation Specificity in *exo1* Δ and *msh3* Δ strains

MMR of -T in a run of Ts in *pol3-L612M*

| Strain | Rate ($\times 10^{-7}$) |
|---|---------------------------|
| MSH2 | 0.006 |
| <i>msh2</i> Δ | 37 |
| <i>msh6</i> Δ | 0.54 |
| <i>msh3</i> Δ | 0.05 |
| <i>msh3</i> Δ <i>msh6</i> Δ | 19 (synergy) |

Mutation Specificity in *exo1* Δ and *msh3* Δ strains

MMR of -T in a run of Ts in *pol3-L612M*

| Strain | Rate ($\times 10^{-7}$) |
|---|---------------------------|
| MSH2 | 0.006 |
| <i>msh2</i> Δ | 37 |
| <i>msh6</i> Δ | 0.54 |
| <i>msh3</i> Δ | 0.05 |
| <i>msh3</i> Δ <i>msh6</i> Δ | 19 (synergy) |
| <i>exo1</i> Δ | 0.10 |
| <i>exo1</i> Δ <i>msh3</i> Δ | 1.2 (synergy) |

Exo1 preferentially participates in the Msh2•6-dependent MMR pathway

Summary


Exo I in MMR

- Exo I differentially repairs Pol α errors more efficiently than pol δ errors

- Exo I dependent MMR plays a greater role in repairing lagging strand errors compared to leading strand errors

- Exo I is involved in the Msh2-Msh6 sub-pathway of MMR

- In the absence of Exo I most replication errors can still be corrected in an Msh2- dependent manner



Acknowledgements

The DNA Replication Fidelity Group

Thomas Kunkel

Kasia Bebenek
Jessica Williams

Anders Clausen
Alan Clark

Mercedes Arana
Danielle Watt


Scott Lujan
Andres Larrea*

Laboratory of Molecular Genetics

Laboratory of Structural Biology

NIEHS

*former member




First High-Resolution Genome-Wide Map of p53 Binding Sites in Normal Human Cells

**Krassi Botcheva,
Brookhaven National Laboratory, Upton, NY**

**VIDEOCONFERENCE
NIH DNA REPAIR INTEREST GROUP**

**Origin of Videoconference: BNL
TUESDAY JUNE 19 2012 12:30PM**




First High-Resolution Genome-Wide Map of p53 Binding Sites in Normal Human Cells

Krassimira Botcheva

**Assoc Geneticist
Brookhaven National Laboratory, Upton, NY**






The rise of p53

Bert Vogelstein and Carol Prives

2009 Nature Reviews Cancer 9

- Inactivation of p53 is essential for the formation of nearly all cancers.
- The volume of work on p53 has shown it to be at the centre of a cellular network of feedback and feedforward loops, forming a paradigm for system biology.
- Understanding of this network, and determining how it can be exploited for therapeutic benefit, will keep scientists busy for years to come.



➤ Upon DNA damage p53 binds to the genome and regulates transcription of extensive network of genes, promoting cell cycle arrest, DNA repair, senescence or apoptosis.

➤ Unresolved remains the question how p53 discriminates between the thousands of potential p53 binding sites predicted in the human genome.


➤ Individually analyzed functional binding sites are close to the target genes/TSS.


➤ Three major genome-wide studies were published in human cancer-derived cells.

Chip-PET, HCT116, Wei et al, Cell 2006

ChIP-chip, U2OS, Smeenk et al. NAR 2008

ChIP-seq, U2OS, Smeenk et al. PLOS 2011







Where in the genome binds p53 in normal not transformed human cells?

Are these locations similar or different from those reported previously in cancer-derived cell lines?

What is the genomic landscape of the p53 binding sites?



Defining high-confidence p53 binding sites in normal human fibroblasts IMR90




NGS
Illumina

Distinct unique reads
ChIP-seq ~4 million
Input-seq ~8 million


Total number of peaks
~6,800
~2,500


Enriched above Input
~1,700 ChIP-seq peaks

High-confidence
743 ChIP-seq peaks





p53 ChIP-seq and Input-seq map at chr6 and the canonical p53 target CDKN1A








Out of 168 known functional (reference) p53 binding sites, 62 were successfully identified in IMR90




For 79% of the identified reference sites, the distance between the peak maximum and the reference site center was less than 50 nt, and for 52% - less than 20 nt.





p53 ChIP-seq peaks are strongly enriched for predicted p53 binding sites and for TSS






Only in the normal IMR90 cells p53 ChIP-seq peaks are strongly enriched at TSS and CpG islands (CGIs)






In IMR90 cells p53 ChIP-seq peaks are enriched for CpGs and at hypomethylated DNA


p53 ChIP-seq peaks are enriched for CpG dinucleotides




p53 ChIP-seq peaks are hypomethylated




* IMR90 methylation data from Lister et al. Nature, 2009.




p53 ChIP-seq peaks in CGIs and out of CGIs have different hypomethylation profile




* IMR90 methylation data from Lister et al. Nature, 2009.





In IMR90 cells p53 ChIP-seq peaks are enriched at proximal CpG islands



Distribution of all human CGIs with respect to TSS. Plotted in red are CGIs at which high-confidence p53 ChIP-seq peaks are found.




In IMR90 cells p53 ChIP-seq peaks are enriched at hypomethylated DNA




* IMR90 methylation data from Lister et al. Nature, 2009.


The hypomethylation level of ChIP-seq peaks in proximal CGIs matches that of all human proximal CGIs.




In IMR90 cells p53 ChIP-seq peaks are enriched at hypomethylated DNA




* IMR90 methylation data from Lister et al. Nature, 2009.



p53 ChIP-seq peaks in distal CGIs are more hypomethylated than the human distal CGIs.




Motif analysis of the high-confidence ChIP-seq peaks identified in IMR90 cells



Sequence logo depicting the p53CSI motif (ChIP-seq identified in IMR90), E-value $1.2e-1059$.



p53 motif enrichment at the ChIP-seq peaks



Summary


p53 binding sites in the cancer cells HCT116 and U2OS

p53 binding sites in the normal cells IMR90




- Less than 5% within 2kb of TSS
- Depleted from CGIs
- Enriched at repeats
- Methylation status ?

- More than 40% within 2kb of TSS
- Strongly enriched at CGIs
- Less enriched at repeats
- Hypomethylated





Summary

- We provide high-resolution genome-wide map of p53 binding sites in **normal (not transformed) human cells**.
- These sites have **distinct genomic distribution** compared to those previously reported in cancer-derived human cells.
- That distribution **does not reflect p53 affinity to specific sequences**.
- A small fraction of binding sites is present in all four p53 datasets analyzed; **only in the normal cells p53 is highly enriched within 2kb +/- TSS**, distribution characteristic for the individually analyzed functional p53 binding sites.
- In the normal human cells p53 is highly enriched at **CpG islands and hypomethylated DNA**.



Open Questions

- How important for the p53 genome-wide binding is the epigenetic landscape of the human genome?
- How global hypomethylation and local CpG islands hypermethylation accompanying cancer development affect p53 genome-wide binding and target selectivity?
- How Low Dose Radiation and the epigenetic changes caused by it affect p53 binding and DNA damage response in the human cells?



Acknowledgements

Sean McCorkle, BNL

Carl Anderson, BNL

John Dunn, BNL

Mike Blewitt, BNL

Dmitri Kotov, SULI student (BNL)

Dick McCombie, CSHL

Elena Ghiban, CSHL

David Turner, Sanger UK

Joel Rozowsky, Yale

Michael Regulski, CSHL

Paul Wilson, BNL

Tiffany Bowman (BNL, Graphic Design)

This work was supported by the Low Dose Radiation Program (DOE) and LDRD (BNL).



NEXT ?

Genome-wide studies on different types of cells (normal and cancer) combined with DNA methylation and histone modification maps, can help place p53 binding in the context of chromatin in vivo, to address the epigenetic impact on the p53 dependent transcription regulation and to provide a global view of the p53 network changes during cancer progression.

Botcheva et al. Cell Cycle 2011

Role of the Circadian Clock in UV-Induced Skin Carcinogenesis

Shobhan Gaddameedhi

Aziz Sancar Lab

Circadian Rhythm & Circadian Clock

circa, "around," *dies*, "a day"



www.learner.org/jnorth/images

- Circadian Rhythm
- Circadian Clock
- Synchronized with the solar clock by light

Circadian clock disruption




- Sleep Disorder
- Jet Lag

Clock related diseases

- Cancer
- Heart attack
- Type 2 diabetes


Loss of Rhythmic Behavior in Clock-deficient Mice

Actogram: Wheel running activity






Vitaterna *et al.* PNAS (1999) 96, 12114-12119


Role of the Excision Repair in preventing UV-induced Skin Carcinogenesis





Circadian Oscillation of NER Activity and XPA Levels in Mouse Liver and Brain







Potential importance of Rhythmic Expression of NER Activity in Skin Cancer Incidence?





Circadian Oscillation of XPA in Mouse Skin




Circadian Rhythmicity of Excision Repair Rate in Mouse Epidermis



Circadian Rhythmicity of DNA Replication in Mouse



Does Skin Cancer Incidence Depend on Time of Day?



Skin Carcinogenesis Protocol

- Irradiate Mice with UVB 3 times a week for 25 weeks:
 - AM Group – 4 AM (ZT 21),
 - PM Group – 4 PM (ZT 09)
 - Control Group- No Treatment
- Examine skin daily for 25 weeks
- Analyze skin lesions histopathologically



Effect of Time of Day on UV- Skin Carcinogenesis (Visual Diagnosis) in Mouse




Control

AM


PM



Effect of Time of Day on UV- Skin Carcinogenesis (Histopathological Examination) in Mouse



Conclusion: Model for the Role of Circadian Clock in UV-induced Skin Carcinogenesis



Acknowledgment



Dr. Aziz Sancar

Sancar Lab

Dr. Christopher P. Selby

Dr. Laura Lindsey-Boltz

Dr. Michael Kemp

Dr. Joyce Reardon

Dr. Christopher Capp

Dr. Rui Ye

Other Members of the Lab

Dr. Marila Cordeiro-Stone -UNC-CH

Dr. William K. Kaufmann -UNC-CH

Dr. Robert Smart -NC State

Questions?

November 15, 2011 | vol. 108 | no. 46 | 18567–18854

In This Issue

PNAS

Proceedings of the National Academy of Sciences of the United States of America

www.pnas.org

Time of UV exposure might influence skin cancer onset

Exposure to UV radiation triggers DNA lesions that can lead to skin cancer, the most common type of cancer in the United States. Previous studies in mice have shown that levels of a protein called XPA, involved in repairing UV-induced DNA lesions, waxes and wanes with the time of day, peaking between 4–6 PM and dipping between 4–6 AM in tune with the circadian clock. Shobhan Gaddameedhi et al. (pp. 18790–18795) found that the protein's level and activity in mouse skin cells are at their lowest at 4 AM and their highest at 4 PM. The authors exposed two groups of mice to UV radiation—one at 4 AM and the other at 4 PM—and monitored the onset of skin cancer. Mice irradiated when the repair activity was at its lowest developed tumors much faster and at five-fold higher frequency compared with mice exposed to UV when the protein's repair function was at full throttle. When the authors repeated the experiment in a strain of mice lacking two key components of the circadian clock, the time of UV exposure tracked neither the protein's repair activity nor the onset of skin cancer, suggesting that circadian control of the XPA protein might influence skin cancer rates. Because mouse and human circadian clocks are similar, the time of UV exposure might likewise determine its cancer-causing potential in people, according to the authors. — P.N.



Circadian control of skin cancer.

Image courtesy of Marian Miller (University of Cincinnati, Cincinnati, OH), Upper left quadrant: Hourtide by Edward Henry Potthast, 1920; Lower left quadrant: Sleeping Woman by Felix Vallotton, 1899.

Gaddameedhi S *et al* (2011) PNAS 108:18790-18795